Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 441-445

  Wenzel, Catharina ^a   Bartsch, Rupert ^a   Locker, Gottfried J ^a   Hussian, Dagmar ^a   Pluschnig, Ursula ^a   Sevelda, Ursula ^a   Gnant, Michael F ^a   Jakesz, Raimund ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Capecitabine; Docetaxel; Epidoxorubicin; Neoadjuvant; Pegfilgrastim

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FILGRASTIM; GLUCURONATES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PILOT PROJECTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 20144389747     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00011     Document Type: Article

References (12)

1. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
2. Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MF, et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor. Anticancer Drugs 2002; 13:67-74.
3. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000; 18:2369-2377.
4. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
5. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res; 4:1013-1019.
6. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
7. Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol 2002; 13:546-552.
8. Venturini M, Durando A, Garrone O, Colozza MA, Contu A, Stevani I, et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast cancer. Cancer 2003; 97: 1174-1180.
9. 2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996; 74:650-656.
10. De Matteis A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 2002; 94:895-901.
11. Milla-Santos A, Milla L, Rallo L, Solano V. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 2001; 24: 138-142.
12. Steger GG, Kubista E, Hausmaninger H, Gnant M, Tausch C, Lang H and the Austrian Breast and Colorectal Cancer Study Group. 6 vs. 3 cycles of epidoxorubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. Proc Am Soc Clin Oncol 2004; 22:14S (abstr 553).